MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
31.05
+0.09
+0.29%
Pre Market: 31.11 +0.06 +0.19% 06:08 12/05 EST
OPEN
30.23
PREV CLOSE
30.96
HIGH
31.54
LOW
30.10
VOLUME
2.84K
TURNOVER
0
52 WEEK HIGH
38.69
52 WEEK LOW
5.35
MARKET CAP
1.77B
P/E (TTM)
47.05
1D
5D
1M
3M
1Y
5Y
1D
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Simply Wall St · 5h ago
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating
Seeking Alpha · 18h ago
Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples?
Simply Wall St · 2d ago
Biogen And Stoke Therapeutics To Present Data From Studies Of Zorevunersen At 2025 AES Annual Meeting
Benzinga · 4d ago
Stoke Therapeutics Reports Zorevunersen Shows Disease-Modifying Effects in Dravet Syndrome Study
Reuters · 4d ago
Weekly Report: what happened at STOK last week (1124-1128)?
Weekly Report · 4d ago
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Barchart · 4d ago
Can Stoke Therapeutics (STOK) Translate Natural History Data Into a Competitive Edge for Dravet Therapy?
Simply Wall St · 6d ago
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.